EMA approvals

Market Access

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike

Market Access

The FDA released its overview of 2023 and the drugs it had approved during the year.

News

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.